Persson S
Department of Cardiology, Malmo University Hospital, Sweden.
J Hypertens Suppl. 1995 Aug;13(2):S57-63. doi: 10.1097/00004872-199508001-00009.
To review the results of recent studies on the use of angiotensin converting enzyme (ACE) inhibitors and calcium antagonists in patients after an acute myocardial infarction.
Literature review.
ACE inhibition reduces mortality and morbidity and improves quality of life in a cost-effective way, demonstrating increased benefits with increasing risks. Calcium antagonism with verapamil and possibly diltiazem reduces mortality and morbidity, except in patients with congestive heart failure without signs of reversible myocardial ischaemia. Nifedipine may have negative effects. The efficacy of the second-generation dihydropyridines remains to be demonstrated.
回顾近期关于急性心肌梗死后患者使用血管紧张素转换酶(ACE)抑制剂和钙拮抗剂的研究结果。
文献综述。
ACE抑制以具有成本效益的方式降低死亡率和发病率,并改善生活质量,显示出风险越高获益越大。维拉帕米以及可能地尔硫䓬的钙拮抗作用可降低死亡率和发病率,但充血性心力衰竭且无可逆性心肌缺血迹象的患者除外。硝苯地平可能有负面影响。第二代二氢吡啶类药物的疗效仍有待证实。